New drug iptacopan aims to save lives in rare transplant complication
NCT ID NCT07347990
First seen Jan 19, 2026 · Last updated Jun 08, 2026 · Updated 18 times
Summary
This study tests a new oral drug, Iptacopan, for a serious condition called TA-TMA that can happen after a stem cell transplant. TA-TMA damages small blood vessels and can be life-threatening. The trial will include 30 people aged 12 and older who have not improved with initial treatments. The main goal is to see if Iptacopan helps more patients survive for 6 months after diagnosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC MICROANGIOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China, 310003, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.